Table 2.

Influence of DNMT3B SNP on the risk of development and lymphatic metastases of GCA.

Group	DNMT3B genotype T/T	n (%) C/T	aOR (95%CI)	P
Overall
Control	279 (94.9)	15 (5.1)
GCA	205 (96.7)	7 (3.3)	0.66 (0.26-1.67)	0.38
Nonsmoker
Control	130 (96.3)	5 (3.7)
GCA	78 (95.1)	4 (4.9)	1.43 (0.37-5.56)	0.61
Smoker
Control	98 (95.1)	5 (4.9)
GCA	111 (97.4)	3 (2.6)	0.61 (0.14-2.69)	0.51
Family history of UGIC in
GCA patients	82 (96.5)	3 (3.5)	0.40(0.05-3.14)	0.38
Positive	97 (96.0)	4 (4.0)	0.94 (0.35-2.50)	0.91
Negative
GCA with LM data
LM- (n = 62)	58 (93.5)	4 (6.5)
LM+(n = 69)	67 (97.1)	2 (2.9)	0.45 (0.08-2.63)	0.38

LM: lymphatic metastasis.